PMID- 32162559
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20220414
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 21
IP  - 8
DP  - 2020 Jun
TI  - Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the 
      treatment of non-small cell lung cancer.
PG  - 931-940
LID - 10.1080/14656566.2020.1738387 [doi]
AB  - INTRODUCTION: Anaplastic lymphoma kinase (ALK) inhibitors are potent oral 
      anti-cancer agents acting as tyrosine kinase inhibitors (TKIs), which are 
      approved for the treatment of ALK+ non-small cell lung cancer (NSCLC). Over the 
      last years, several new molecules have been developed and are currently under 
      clinical investigation. AREAS COVERED: In this paper, the authors review the most 
      relevant clinical findings of ALK inhibitors in the treatment of ALK+ NSCLC. The 
      authors discuss differences in the efficacy and treatment-related adverse events 
      (AEs) incidence of distinct ALK inhibitors, molecular mechanisms of acquired 
      resistance, and ongoing clinical studies assessing the use of ALK inhibitors in 
      innovative settings and novel combinations. EXPERT COMMENTARY: ALK inhibitors 
      have dramatically improved the prognosis of patients with ALK+ NSCLC and 
      revolutionized therapy options. Nowadays, several molecules are approved for the 
      treatment of ALK+ NSCLC, either in first or further lines of systemic treatment. 
      Several clinical trials are currently ongoing in order to define a potential role 
      of ALK inhibitors in combination with novel anti-cancer agents, as well as 
      monotherapy in neo- and adjuvant settings.
FAU - Indini, Alice
AU  - Indini A
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Rijavec, Erika
AU  - Rijavec E
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Ghidini, Michele
AU  - Ghidini M
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Bareggi, Claudia
AU  - Bareggi C
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Gambini, Donatella
AU  - Gambini D
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Galassi, Barbara
AU  - Galassi B
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Antonelli, Paola
AU  - Antonelli P
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Bettio, Giulia
AU  - Bettio G
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Di Nubila, Clarissa
AU  - Di Nubila C
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
FAU - Grossi, Francesco
AU  - Grossi F
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200312
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/*antagonists & inhibitors
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Non-small cell lung cancer
OT  - alectinib
OT  - brigatinib
OT  - ceritinib
OT  - crizotinib
OT  - ensartinib
OT  - lorlatinib
EDAT- 2020/03/13 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/03/13 06:00
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/03/13 06:00 [entrez]
AID - 10.1080/14656566.2020.1738387 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2020 Jun;21(8):931-940. doi: 
      10.1080/14656566.2020.1738387. Epub 2020 Mar 12.